# Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors.

> **NCT07303387** · PHASE2 · RECRUITING · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 900 (estimated)

## Conditions studied

- Solid Tumor Malignancies
- Clear Cell Endometrial Carcinoma
- Ovarian Cancer

## Interventions

- **DRUG:** Valemetostat Tosylate

## Key facts

- **NCT ID:** NCT07303387
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-05
- **Primary completion:** 2031-02-28
- **Final completion:** 2032-02-28
- **Target enrollment:** 900 (ESTIMATED)
- **Last updated:** 2026-04-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07303387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07303387, "Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07303387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*